Glenzocimab for COVID-19: real-time analysis

Download Image

Post

c19early.org

Glenzocimab for COVID-19

1 study with 62 patients

Serious outcome risk

Glenzocimab

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Glenzocimab studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−60%

RCTs (1)−60%

Early (1)−60%

00.511.5+

← Glenzocimab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Jun 17 2024	Pottecher et al., PLOS ONE, doi:10.1371/journal.pone.0302897	Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial
Jun 17 2024	RCT 61 hospitalized COVID-19 patients showing no significant difference in primary outcomes with glenzocimab (an anti-GPVI antibody) vs. placebo. Authors report glenzocimab showed a significant improvement in the NEWS-2 category at day 4,..